Literature DB >> 21686597

Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia.

Brigitte Granel1, Pascal Rossi, Fanny Bernard, Isabelle Dettori, Regis Costello, Anne Laurence Demoux, Denis Bagneres, Pierre Lafforgue, Yves Frances.   

Abstract

Mixed warm and cold autoimmune anaemia is a rare haemolytic anaemia that is commonly associated with lymphoproliferative disorders and autoimmune diseases. Although steroid therapy is the first-line treatment, rituximab represents a good alternative. The present study reports on a successful treatment with rituximab in a young woman suffering from a mixed warm and cold autoimmune haemolytic anaemia associated with a mixed connective tissue disease.

Entities:  

Year:  2009        PMID: 21686597      PMCID: PMC3028234          DOI: 10.1136/bcr.09.2008.0857

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment.

Authors:  Monica Morselli; Mario Luppi; Leonardo Potenza; Stephanie Tonelli; Daniele Dini; Giovanna Leonardi; Amedea Donelli; Franco Narni; Giuseppe Torelli
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

2.  Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy.

Authors:  P Rossi; A L Demoux; B Granel; D Bagnères; S Bonin-Guillaume; Y Frances
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

3.  A patient with mixed connective tissue disease and mixed-type autoimmune hemolytic anemia.

Authors:  Yuan S Kao; Karen C Kirkley
Journal:  Transfusion       Date:  2005-11       Impact factor: 3.157

4.  A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy.

Authors:  M Haroon; D O'Gradaigh; D Foley-Nolan
Journal:  Rheumatology (Oxford)       Date:  2007-02-08       Impact factor: 7.580

5.  Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy response.

Authors:  L Dunkley; M Green; A Gough
Journal:  Rheumatology (Oxford)       Date:  2007-09-01       Impact factor: 7.580

6.  [Autoimmune anemia and thrombopenia in mixed connective tissue disease].

Authors:  E Talesnik; H Taboada; S Rivero; S Jacobelli
Journal:  Rev Chil Pediatr       Date:  1983 Mar-Apr

7.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

Authors:  Marco Zecca; Bruno Nobili; Ugo Ramenghi; Silverio Perrotta; Giovanni Amendola; Pasquale Rosito; Momcilo Jankovic; Paolo Pierani; Piero De Stefano; Mario Regazzi Bonora; Franco Locatelli
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

8.  Autoimmune hemolytic anemia with both cold and warm autoantibodies.

Authors:  I A Shulman; D R Branch; J M Nelson; J C Thompson; S Saxena; L D Petz
Journal:  JAMA       Date:  1985 Mar 22-29       Impact factor: 56.272

9.  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen; Henrik Hjorth-Hansen; Ruth Langholm; Håvar Knutsen; Waleed Ghanima; Fuad Victor Shammas; Geir E Tjønnfjord
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

10.  Rituximab therapy for childhood Evans syndrome.

Authors:  Brigitte Bader-Meunier; Nathalie Aladjidi; Françoise Bellmann; Fabrice Monpoux; Brigitte Nelken; Alain Robert; Corinne Armari-Alla; Capucine Picard; Françoise Ledeist; Martine Munzer; Karima Yacouben; Yves Bertrand; Antoine Pariente; Arnaud Chaussé; Yves Perel; Guy Leverger
Journal:  Haematologica       Date:  2007-12       Impact factor: 9.941

View more
  1 in total

Review 1.  Rituximab in the treatment of autoimmune haemolytic anaemia.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Lallindra Gooneratne
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.